AGM/EGMJun 10, 2026, 04:07 PM
Aquestive Therapeutics Elects Directors, Ratifies Auditor
AI Summary
Aquestive Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders on June 10, 2026. Stockholders elected Gregory B. Brown, M.D., John S. Cochran, and Abigail L. Jenkins as Class II members to the Board of Directors for a three-year term. Additionally, the proposal to approve executive compensation on a non-binding advisory basis was passed, and KPMG LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Key Highlights
- Gregory B. Brown, M.D. elected as Class II Director with 41,373,033 votes for a three-year term.
- John S. Cochran elected as Class II Director with 36,914,899 votes for a three-year term.
- Abigail L. Jenkins elected as Class II Director with 39,094,166 votes for a three-year term.
- Executive compensation approved on a non-binding advisory basis with 37,798,609 votes for.
- KPMG LLP ratified as independent auditor for fiscal year 2026 with 78,804,323 votes for.
Price Impact
More from AQST